Polemics of pioglitazone: an appraisal in 2015

References

• Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58(4):773-95
   PubMed Web of Science ®Google Scholar
• Yajnik CS, Yudkin JS. The Y-Y paradox. Lancet 2004;363(9403):163
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Bach RG, Brooks MM, Lombardero M, et al. BARI 2D Investigators. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 2013;128:785-94
   PubMed Web of Science ®Google Scholar
• Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34(4):916-22
   PubMed Web of Science ®Google Scholar
• Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population based cohort study. Diabetologia 2012;55(7):1953-62
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (2010) FDA drug safety communication: ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. Available from: www.fda.gov/drugs/drugsafety/ucm226214.htm [Last accessed 25 Nov 2014]
   Google Scholar
• European Medicines Agency (2011) European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001311.jsp&mid=WC0b01ac058004d5c1 [Last accessed 25 Nov 2014]
   Google Scholar
• Unnikrishnan R, Sundramoorthy C, Deshpande N, et al. Eight cases of bladder cancer in pioglitazone users from India. J Assoc Phys India 2012;60:66
   PubMedGoogle Scholar
• Yamanouchi T, Sakai T, Iqarashi K, et al. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med 2005;22(8):980-5
   PubMed Web of Science ®Google Scholar
• Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006;22(4):751-9
   PubMed Web of Science ®Google Scholar
• Perriello G, Pampanelli S, Di Pietro C, Brunetti P. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. Diabet Med 2006;23(3):246-52
   PubMed Web of Science ®Google Scholar
• Liu SC, Chien KL, Wang CH, et al. Efficacy and Safety of Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Insufficiently Controlled with Metformin and a Sulfonylurea. Endocr Pract 2013;19(6):980-8
   PubMed Web of Science ®Google Scholar
• Roden M, Laakso M, Johns D, et al. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. Diabet Med 2005;22(8):1101-6
   PubMed Web of Science ®Google Scholar
• Betteridge DJ, Vergès B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 2005;48(12):2477-81
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Puckett C, Adam J. Initial triple combination therapy is superior to stepwise add-on conventional therapy in newly diagnosed T2DM. Diabetes 2013;62(Suppl 1):A97
   Google Scholar
• Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48(6):1093-104
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43
   PubMed Web of Science ®Google Scholar
• Home PD, Kahn SE, Jones NP, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010;53(9):1838-45
   PubMed Web of Science ®Google Scholar
• Pyorala M, Miettinen H, Halonen P, et al. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000;20(2):538-44
   PubMed Web of Science ®Google Scholar
• Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002;25(7):1135-41
   PubMed Web of Science ®Google Scholar
• Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006;49:434-41
   PubMed Web of Science ®Google Scholar
• Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabete Metab 1986;12:346-50
   PubMed Web of Science ®Google Scholar
• Højlund K, Glintborg D, Andersen NR, et al. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes 2008;57(2):357-66
   PubMed Web of Science ®Google Scholar
• Rabøl R, Boushel R, Almdal T, et al. Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. Diabetes Obes Metab 2010;12(9):806-14
   PubMed Web of Science ®Google Scholar
• Fiorentino TV, Daniele G, Tripathy D, et al. Low dose pioglitazone-induced reduction in skeletal muscle TACE activity and TNFalpha is associated with an improvement of glycaemic control in type 2 diabetic patients. Poster 611, EASD Barcelona 2013
   Google Scholar
• Marx N. PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes. Diab Vasc Dis Res 2008;5(4):345-6
   PubMed Web of Science ®Google Scholar
• Betteridge DJ. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fundam Clin Pharmacol 2009;23(6):675-9
   PubMed Web of Science ®Google Scholar
• Patel DK, Walitt B, Lindsay J, Wilensky RL. Pioglitazone in the prevention of restenosis and need for revascularisation after bare metal implantation: a metanalysis. Cardiovasc Interv 2011;4(3):353-60
   PubMed Web of Science ®Google Scholar
• Marx N, Wöhrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in non-diabetic patients. Circulation 2005;112(18):2792-8
   PubMed Web of Science ®Google Scholar
• Hughes AD, Park C, March K, et al. A randomised placebo controlled double blind crossover trial of pioglitazone in left ventricular diastolic function in type 2 diabetes. Int J Cardiol 2013;167(4):1329-32
   PubMed Web of Science ®Google Scholar
• Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an Observational Study. Circulation 2005;111:583-90
   PubMed Web of Science ®Google Scholar
• Giles TD, Elkayam U, Bhattacharya M, et al. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest Heart Fail 2010;16(3):111-17
   PubMedGoogle Scholar
• Goldstein MR. PROactive study. Lancet 2006;367(9504):23-6
   PubMedGoogle Scholar
• Perez A, Song E, Edmonds A. MACE associated with pioglitazone: meta-analysis of randomised controlled trial. EASD 2013 Berlin – poster 1230
   Google Scholar
• Boyle P, Boniol M, Koechlin A, et al. Safety of glucose lowering medication: The diabetes adverse event monitor (DIABAMON) project: II cardiovascular disease. Diabetes 2013;1405-P:A367
   Google Scholar
• Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76
   PubMed Web of Science ®Google Scholar
• Brunelli SM, Thadhani R, Ikizler TA, Feldman HI. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int 2009;75:961-8
   PubMed Web of Science ®Google Scholar
• Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-409
   PubMed Web of Science ®Google Scholar
• Matthews DR, Charbonnel BH, Hanefeld M, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005;21:167-74
   PubMed Web of Science ®Google Scholar
• Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82-90
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-83
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Ragonesi PD, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J 2007;37:79-86
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364(12):1104-15
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Fogari E, et al. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Horm Metab Res 2011;43(7):505-12
   PubMed Web of Science ®Google Scholar
• Derosa G, Mereu R, D’Angelo A, et al. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. J Clin Pharm Ther 2010;35(5):565-79
   PubMed Web of Science ®Google Scholar
• Khan S, Khan S, Imran M, et al. Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus – targeting thrombogenesis. Expert Opin Ther Targets 2013;17(6):627-39
   PubMed Web of Science ®Google Scholar
• Pfützner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45(12):1925-31
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Pfützner A, Forst T, et al. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc Diabetol 2011;10:65
   PubMed Web of Science ®Google Scholar
• Pfützner A, Schöndorf T, Tschope D, et al. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther 2011;13(6):637-43
   PubMed Web of Science ®Google Scholar
• Sepanjnia K, Modabernnia A, Ashrafi M, et al. Pioglitazone Adjunctive Therapy for Moderate-to-Severe Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Trial. Neuropsychopharmacology 2012;37:2093-100
   PubMed Web of Science ®Google Scholar
• Kaiser CC, Shukla DK, Stebbins GT, et al. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol 2009;211(1–2):124-30
   PubMed Web of Science ®Google Scholar
• Malhotra A, Safiq N, Rajagopalan S, et al. TZD for plaque psoriasis: A systemic reviews and metanalysis. Evid Based Med 2012;17(6):171-6
   PubMedGoogle Scholar
• Gastaldelli A, Harrison S, Belfort-Aquiar R, et al. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther 2010;32(6):769-75
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med 2010;362(18):1675-85
   PubMed Web of Science ®Google Scholar
• Maffioli P, Fogari E, D’Angelo A, et al. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. Eur J Gastroenterol Hepatol 2013;25(9):1113-22
   PubMed Web of Science ®Google Scholar
• Derosa G. Pioglitazone is a valid alternative to rosiglitazone. Am J Cardiovasc Drugs 2011;11(6):357-62
   PubMed Web of Science ®Google Scholar
• Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010;70(15):1945-61
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 2012;5(2):272-81
   PubMedGoogle Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
   PubMed Web of Science ®Google Scholar
• Katoh S, Mori Y, Yokoyama J. Effect of oral hypoglycaemic agents on fat distribution and glucose tolerance in non-insulindependent diabetes mellitus patients. J Jpn Diabetes Soc 1998;41:289-93
   Google Scholar
• Diamant M, Heine R. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003;63:1373-405
   PubMed Web of Science ®Google Scholar
• Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009;11:1091-9
   PubMed Web of Science ®Google Scholar
• Chang CH, Lin JW, Wu LC, et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012;55(5):1462-72
   PubMed Web of Science ®Google Scholar
• Ohta K, Endo T, Haraquchi K, et al. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:2170-7
   PubMed Web of Science ®Google Scholar
• Takano S, Kubota T, Nishibori H, et al. Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. Anticancer Res 2008;28(6A):3593-9
   PubMed Web of Science ®Google Scholar
• Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007;16:485-92
   PubMed Web of Science ®Google Scholar
• Blanquicett C, Roman J, Hart CM. TZD as an anticancer drug. Cancer Ther 2008;6A:25-34
   Google Scholar
• Yang X, So WY, Ma RC, et al. Use of thiazolidinedione and cancer risk in Type 2 diabetes: the Hong Kong diabetes registry. Diabetes Res Clin Pract 2012;97(1):e13-17
   Web of Science ®Google Scholar
• Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011;34(6):1369-71
   PubMed Web of Science ®Google Scholar
• Lewis JD, Ferrara A, Strom BL, et al. Cohort study of pioglitazone and bladder cancer in patients with diabetes: fourth interim analysis (8-year) report with data from January 1, 1997 to December 31, 2010. Available from: http://general.takedapharm.com/Trial-Disclosure/01-03-TL-OPI-524-8-year-Interim-Report.pdf [Last accessed on 25 November 2014]
   Google Scholar
• Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case–control study. BMJ 2012;344:e3645
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Hamamoto Y, Honjo S, et al. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2013;99:e21-3
   PubMed Web of Science ®Google Scholar
• Hsiao FY, Hsieh PH, Huang WF, et al. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case-control study. Drug Saf 2013;36:643-9
   PubMed Web of Science ®Google Scholar
• Zhu Z, Shen Z, Lu Y, et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2012;98(1):159-63
   PubMed Web of Science ®Google Scholar
• Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinedionesand the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012;184(12):E675-83
   PubMed Web of Science ®Google Scholar
• Kermode-Scott B. Meta-analysis confirms raised risk of bladder cancer from pioglitazone. BMJ 2012;345:e4541
   Google Scholar
• Bosetti C, Rosato V, Buniato D, et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 2013;18(2):148-56
   PubMed Web of Science ®Google Scholar
• Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med 2013;30(9):1026-32
   PubMed Web of Science ®Google Scholar
• Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr Clin Res Rev 2008;2:47-57
   Google Scholar
• European Medicines Agency. Assessment report for Actos, Glustin, Competact, Glubrava, Tandemact. 2011. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000285/WC500126656.pdf
   Google Scholar
• Li W, Macdonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 2013;75(1):254-9
   PubMed Web of Science ®Google Scholar
• Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012;35(2):278-80
   PubMed Web of Science ®Google Scholar
• Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst 2012;104(18):1411-21
   PubMedGoogle Scholar
• Chang CH, Lin JW, Wu LC, et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012;55(5):1462-72
   PubMed Web of Science ®Google Scholar
• Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 2013;75:254-9
   PubMed Web of Science ®Google Scholar
• Song SO, Kim KJ, Lee BW, et al. The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone. Diabetes Metab J 2012;36:371-8
   PubMedGoogle Scholar
• Romero V, Peyton C, Gray I, et al. Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use. BMC Urol 2014;14:10
   PubMed Web of Science ®Google Scholar
• Kuo HW, Tiao MM, Ho SC, Yang CY. Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci 2014;30:94-7
   PubMed Web of Science ®Google Scholar
• Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Available from: www.takeda.com/news/2014/20140829_6714.html [Last accessed 3 January 2015]
   Google Scholar
• Spanheimer R, Erdmann E, Song E, et al. Pioglitazone and bladder malignancy during observational follow-up of PROactive: 6-year update. European Association for the Study of Diabetes 2012 Meeting; 4 ctober 2012; Berlin, Germany. Presentation 787
   Google Scholar
• Monami M, Dicembrini I, Manucci E. Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetol 2014;51(1):91-101
   PubMed Web of Science ®Google Scholar
• Available from: www.diabetologists.org.uk/Shared_Documents/position_papers/ABCD.DUK_joint_pioglitazone_submission_to_MHRA.pdf [Last accessed on 25 November 2014]
   Google Scholar
• Available from: www.fda.gov/drugs/drugsafety/ucm259150.htm [Last accessed on 25 November 2014]
   Google Scholar
• Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001311.jsp&mid=WC0b01ac058004d5c1 [Last accessed on 25 November 2014]
   Google Scholar
• Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/10/news_detail_001368.jsp&mid=WC0b01ac058004d5c1 [Last accessed on 25 November 2014]
   Google Scholar
• Balaji V. Efficacy and safety of pioglitazone in type 2 diabetes in the Indian patients: Results of an observational study. Indian J Endocrinol Metab 2013;17(4):709-15
   PubMedGoogle Scholar
• Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and bladder cancer: Lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2012;30:368-402
   PubMed Web of Science ®Google Scholar
• The Emerging Risk Factor Collaboration. Seshsai SR, Kapotge S, Thompson A, et al. Diabetes Mellitus, Fasting Glucose and Risk of Cause-Specific Death. NEJM 2011;364:829-41
   PubMed Web of Science ®Google Scholar
• Notani PN. Global variation in cancer incidence and mortality. Curr Sci 2001;81(5):465-70
   Web of Science ®Google Scholar
• Yang X, Chan JC. Comment: analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer. Diabetes Care 2011;34(8):e136
   Google Scholar
• De Vries F, Zeegers M Goossense ME. Pioglitazone and bladder cancer: two studies, same database, two answers. Br J Clin Pharmacol 2013;76(3):484-5
   PubMed Web of Science ®Google Scholar
• Govindan J, Evans M. Pioglitazone in clinical practice: where are we now? Diabetes Ther 2012;3(1):1-8
   PubMedGoogle Scholar
• Lewis JD, Habel L, Quesenberry C, et al. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. Pharmacoepidemiol Drug Saf 2014;23(6):636-45
   PubMed Web of Science ®Google Scholar
• Tseng CH. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? J Formos Med Assoc 2012;111(3):123-31
   PubMed Web of Science ®Google Scholar
• Scherbaum WA, Goodall G, Erny-Albrecht KM, et al. Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: A German perspective. Cost Eff Resour Alloc 2009;7:9
   PubMedGoogle Scholar
• Brändle M, Goodall G, Erny-Albrecht KM, et al. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Med Wkly 2009;139:173-84
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Bottomley JM, Palmer AJ, et al. PROactive 06: Cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet Med 2007;24:982-1002
   PubMed Web of Science ®Google Scholar
• Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-25
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Currie CJ, Schernthaner GH. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care 2013;36(suppl 2):S155-61
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
   PubMed Web of Science ®Google Scholar